Sarcosine and decreased risk for prostate cancer in schizophrenia

Open Clinical Chemistry Journal

Volumn 2, Issue , 2009, Pages 22-23

  Hashimoto, Kenji ^a  

^a CHIBA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NEUROLEPTIC AGENT; SARCOSINE;

BIPOLAR DISORDER; CANCER GROWTH; CANCER INCIDENCE; CANCER RISK; CLINICAL TRIAL; HEREDITY; HUMAN; PRIORITY JOURNAL; PROSTATE CANCER; SCHIZOPHRENIA; SHORT SURVEY;

EID: 77953426173     PISSN: None     EISSN: 18742416     Source Type: Journal    
DOI: 10.2174/1874241600902010022     Document Type: Short Survey

References (16)

1. Mortensen, P.B. The incidence of cancer in schizophrenic patients. J. Epidemiol. Commun. Health, 1989, 43, 43-47.
2. Hippisley-Cox, J.; Vinogradova, Y.; Coupland, C.; Parker, C. Risk of malignancy in patients with schizophrenia or bipolar disorder: nested casecontrol study. Arch. Gen. Psychiatry, 2007, 64, 1368-1376.
3. Lichtermann, D.; Ekelund, J.; Pukkala, E.; Tanskanen, A.; Lonnqvist, J. Incidence of cancer among persons with schizophrenia and their relatives. Arch. Gen. Psychiatry, 2001, 58, 573-578.
4. Torrey, E.F. Prostate cancer and schizophrenia. Urology, 2006, 68, 1280-1283.
5. Dalton, S.O.; Johansen, C.; Poulsen, A.H.; Nørgaard, M.; Sørensen, H.T.; McLaughlin, J.K.; Mortensen, P.B.; Friis, S. Cancer risk among users of neuroleptic medication: a population-based cohort study. Br. J. Cancer, 2006, 95, 934-939.
6. Sreekumar, A.; Poisson, L.M.; Rajendiran, T.M.; Khan, A.P.; Cao, Q.; Yu, J.; Laxman, B.; Mehra, R.; Lonigro, R.J.; Li, Y.; Nyati, M.K.; Ahsan, A.; Kalyana-Sundaram, S.; Han, B.; Cao, X.; Byun, J.; Omenn, G.S.; Ghosh, D.; Pennathur, S.; Alexander, D.C.; Berger, A.; Shuster, J.R.; Wei, J.T.; Varambally, S.; Beecher, C.; Chinnaiyan, A.M. Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. Nature, 2009, 457, 910-914.
7. Chen, Y.M.; Chen, L.Y.; Wong, F.H.; Lee, C.M.; Chang, T.J.; Yang-Feng, T.L. Genomic structure, expression, and chromosomal localization of the human glycine N-methyltransferase gene. Genomics, 2000, 66, 43-47.
8. Abate-Shen, C.; Shen, M.M. The prostate-cancer metabolome. Nature, 2008, 457, 799-800.
9. Hashimoto, K.; Fukushima, T.; Shimizu, E.; Komatsu, N.; Watanabe, H.; Shinoda, N.; Nakazato, M.; Kumakiri, C.; Okada, S.; Hasegawa, H.; Imai, K.; Iyo, M. Decreased serum levels of D-serine in patients with schizophrenia: evidence in support of the NMDA receptor hypofunction hypothesis of schizophrenia. Arch. Gen. Psychiatry, 2003, 60, 572-576.
10. Hashimoto, K.; Okamura, N.; Shimizu, E.; Iyo, M. Glutamate hypothesis of schizophrenia and approach for possible therapeutic drugs. Curr. Med. Chem. CNS Agents, 2004, 4, 147-154.
11. Hashimoto, K.; Shimizu, E.; Iyo, M. Dysfunction of glia-neuron communication in pathophysiology of schizophrenia. Curr. Psychiatry Rev., 2005, 1, 151-163.
12. Hashimoto, K. Glycine transporter inhibitors as therapeutic agents for schizophrenia. Recent Pat. CNS Drug Discov., 2006, 1, 43-53.
13. Hashimoto, K. The NMDA receptor hypofunction hypothesis for schizophrenia and glycine modulatory sites on the NMDA receptors as potential therapeutic drugs. Clin. Psychopharmacol. Neurosci., 2006, 4, 3-10.
14. Javitt, D.C. Glycine transport inhibitors and the treatment of schizophrenia. Biol. Psychiatry, 2008, 63, 6-8.
15. Lane, H.Y.; Chang, Y.C.; Liu, Y.C.; Chiu, C.C.; Tsai, G.E. Sarcosine or D-serine add-on treatment for acute exacerbation of schizophrenia: a randomized, double-blind, placebo-controlled study. Arch. Gen. Psychiatry, 2006, 62, 1196-1204.
16. Lane, H.Y.; Liu, Y.C.; Chang, Y.C.; Liau, C.H.; Perng, C.H.; Tsai, G.E. Sarcosine (N-methylglycine) treatment for acute schizophrenia: a randomized, double-blind, study. Biol. Psychiatry, 2008, 63, 9-12.